Predictive Oncology Inc. (NASDAQ:POAI – Get Free Report) saw a large drop in short interest in September. As of September 15th, there was short interest totalling 64,100 shares, a drop of 18.0% from the August 31st total of 78,200 shares. Approximately 1.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 2,700,000 shares, the short-interest ratio is presently 0.0 days.
Wall Street Analyst Weigh In
Separately, HC Wainwright assumed coverage on shares of Predictive Oncology in a report on Monday, August 19th. They issued a “buy” rating and a $3.00 price objective for the company.
Read Our Latest Stock Analysis on Predictive Oncology
Predictive Oncology Price Performance
Predictive Oncology (NASDAQ:POAI – Get Free Report) last issued its earnings results on Tuesday, August 13th. The medical instruments supplier reported ($0.68) earnings per share for the quarter. Predictive Oncology had a negative net margin of 802.69% and a negative return on equity of 200.06%. The company had revenue of $0.28 million for the quarter. On average, equities research analysts expect that Predictive Oncology will post -2.03 earnings per share for the current fiscal year.
About Predictive Oncology
Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.
Further Reading
- Five stocks we like better than Predictive Oncology
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Investing In Preferred Stock vs. Common Stock
- MarketBeat Week in Review – 9/23 – 9/27
- Short Selling: How to Short a Stock
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Receive News & Ratings for Predictive Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Predictive Oncology and related companies with MarketBeat.com's FREE daily email newsletter.